ES2184341T3 - Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio. - Google Patents
Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.Info
- Publication number
- ES2184341T3 ES2184341T3 ES98959929T ES98959929T ES2184341T3 ES 2184341 T3 ES2184341 T3 ES 2184341T3 ES 98959929 T ES98959929 T ES 98959929T ES 98959929 T ES98959929 T ES 98959929T ES 2184341 T3 ES2184341 T3 ES 2184341T3
- Authority
- ES
- Spain
- Prior art keywords
- prevention
- treatment
- dysfunction
- myocardium
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 210000004165 myocardium Anatomy 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 102000005681 phospholamban Human genes 0.000 abstract 1
- 108010059929 phospholamban Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Soil Working Implements (AREA)
- Nonmetallic Welding Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Road Signs Or Road Markings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Fertilizers (AREA)
- Processing Of Meat And Fish (AREA)
- Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
Abstract
Uso de un inhibidor de fosfolambano en la fabricación de un medicamento para uso en la prevención o tratamiento de una disfunción del miocardio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99014697A | 1997-12-12 | 1997-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184341T3 true ES2184341T3 (es) | 2003-04-01 |
Family
ID=25535825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98959929T Expired - Lifetime ES2184341T3 (es) | 1997-12-12 | 1998-12-11 | Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio. |
Country Status (13)
Country | Link |
---|---|
US (1) | US5968959A (es) |
EP (1) | EP1039884B1 (es) |
JP (1) | JP2002508314A (es) |
AT (1) | ATE224187T1 (es) |
AU (1) | AU1565599A (es) |
BR (1) | BR9813549A (es) |
CA (1) | CA2311932A1 (es) |
DE (1) | DE69808131T2 (es) |
DK (1) | DK1039884T3 (es) |
ES (1) | ES2184341T3 (es) |
PT (1) | PT1039884E (es) |
WO (1) | WO1999030696A1 (es) |
ZA (1) | ZA9811180B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
WO2000025804A2 (en) * | 1998-11-02 | 2000-05-11 | The Regents Of The University Of California | A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
EP1728516A1 (en) * | 1998-11-02 | 2006-12-06 | The Regents of the University of California | A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
JP2002062296A (ja) * | 2000-08-22 | 2002-02-28 | Yamaguchi Technology Licensing Organization Ltd | 心不全治療薬のスクリーニング方法 |
ATE423574T1 (de) | 2000-09-11 | 2009-03-15 | Univ California | Dominant-negativer plb mutant zur behandlung der herzerkrankungen |
US7183313B2 (en) * | 2002-08-23 | 2007-02-27 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
US7291604B2 (en) | 2003-09-03 | 2007-11-06 | The General Hospital Corporation | Methods of treating restenosis |
AR055041A1 (es) * | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
FR2970964B1 (fr) * | 2011-01-28 | 2013-12-13 | Univ Claude Bernard Lyon | Nouveaux derives d'azacoumarines presentant une activite inhibitrice des pompes mdr |
US9334256B2 (en) * | 2011-06-15 | 2016-05-10 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
US20200347038A1 (en) | 2014-08-29 | 2020-11-05 | Russell Dahl | Quinolines that modulate serca and their use for treating disease |
US20170281611A1 (en) * | 2014-08-29 | 2017-10-05 | Eiger Biopharmaceuticals, Inc. | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
US11730729B2 (en) | 2020-07-20 | 2023-08-22 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3259635A (en) * | 1962-07-26 | 1966-07-05 | Cassella Farbwerke Mainkur Ag | 7-hydroxy coumarin derivative |
US3515721A (en) * | 1967-06-26 | 1970-06-02 | Cassella Farbwerke Mainkur Ag | 3-tertiary-aminoethyl-4-methyl or phenyl-7-ethoxycarbonylmethoxy - halo or mononitro coumarins and congeners |
IT1088554B (it) * | 1977-11-17 | 1985-06-10 | F I D I A Spa | Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina |
IT1160365B (it) * | 1978-12-19 | 1987-03-11 | F I D I A Spa | Applicazioni in campo farmacologico e terapeutico dell'8-cloro-3-(beta-dietilamincetil)-4-metil-7-etossi-carbonilmetossicumarina cloridrato preparato allo stato puro mediante procedimento selettivo, con particolare riguardo alla sua azione antiaritmica |
BR9810335A (pt) * | 1997-06-25 | 2000-09-05 | Orion Corp | Uso de inibidores de fosfolambano para aumentar o fluxo coronário |
-
1998
- 1998-11-10 US US09/188,707 patent/US5968959A/en not_active Expired - Fee Related
- 1998-12-07 ZA ZA9811180A patent/ZA9811180B/xx unknown
- 1998-12-11 AU AU15655/99A patent/AU1565599A/en not_active Abandoned
- 1998-12-11 WO PCT/FI1998/000976 patent/WO1999030696A1/en active IP Right Grant
- 1998-12-11 DK DK98959929T patent/DK1039884T3/da active
- 1998-12-11 PT PT98959929T patent/PT1039884E/pt unknown
- 1998-12-11 JP JP2000538679A patent/JP2002508314A/ja active Pending
- 1998-12-11 BR BR9813549-0A patent/BR9813549A/pt not_active IP Right Cessation
- 1998-12-11 DE DE69808131T patent/DE69808131T2/de not_active Expired - Fee Related
- 1998-12-11 EP EP98959929A patent/EP1039884B1/en not_active Expired - Lifetime
- 1998-12-11 ES ES98959929T patent/ES2184341T3/es not_active Expired - Lifetime
- 1998-12-11 AT AT98959929T patent/ATE224187T1/de not_active IP Right Cessation
- 1998-12-11 CA CA002311932A patent/CA2311932A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA9811180B (en) | 1999-06-09 |
CA2311932A1 (en) | 1999-06-24 |
US5968959A (en) | 1999-10-19 |
DK1039884T3 (da) | 2002-12-09 |
EP1039884A1 (en) | 2000-10-04 |
DE69808131D1 (de) | 2002-10-24 |
AU1565599A (en) | 1999-07-05 |
JP2002508314A (ja) | 2002-03-19 |
WO1999030696A1 (en) | 1999-06-24 |
DE69808131T2 (de) | 2003-06-05 |
ATE224187T1 (de) | 2002-10-15 |
PT1039884E (pt) | 2003-01-31 |
EP1039884B1 (en) | 2002-09-18 |
BR9813549A (pt) | 2000-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2184341T3 (es) | Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio. | |
AR027968A1 (es) | Una composicion para utilizar en el tratamiento y/o prevencion del sarampion y el uso de dicha composicion para un vehiculo para el tratamiento o prevencion del sarampion | |
CY2006007I1 (el) | Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
ES2157252T3 (es) | Aplicacion del riluzol en el tratamiento del neuro-sida. | |
UY25321A1 (es) | Combinaciones de inhibidor de ace-inhibidor de mmp | |
WO1999020260A3 (en) | The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function | |
BR9913533A (pt) | Processos para tratar hipertensão e composições para uso nos mesmos | |
ECSP034866A (es) | Combinaciones antineoplásticas | |
BR9807523A (pt) | Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids. | |
FR2765483B1 (fr) | Medicament destine a traiter les dysfonctions erectiles | |
ES2167678T3 (es) | Tratamiento y profilaxis de la pancreatitis. | |
FI960850A0 (fi) | Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi | |
AR032422A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca | |
UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
ES2194104T3 (es) | Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos. | |
MX9405371A (es) | Derivado de naftilo. | |
EE200300213A (et) | SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks | |
UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada | |
ES2158017T3 (es) | Revestimiento para los tambores de los molinos de bolas. | |
ES2196769T3 (es) | Uso topico de loperamide para el tratamiento de infecciones microbianas. | |
ES2179302T3 (es) | Formas galenicas y sus utilizaciones. | |
AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 | |
BR0017074A (pt) | Combinações de inibidor de ace-antagonista de vasopressina | |
MX9302142A (es) | Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen. |